Skip to main content

ONCOLOGIA ESTRUCTURAL DEL RECEPTOR DE ANDROGENOS: ARQUITECTURA MULTI-DOMINIO Y DISEÑO RACIONAL DE INHIBIDORES DE LA DIMERIZACION PARA EL CANCER DE PROSTATA

BFU2017-86906-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease

  • Jiménez-Panizo, Alba
  • Pérez, Paloma
  • Rojas Mendoza, Ana M.
  • Fuentes-Prior, Pablo
  • Estébanez-Perpiñá, Eva
18 páginas, 5 figuras, 1 tabla, Nuclear receptors are transcription factors that play critical roles in development, homeostasis and metabolism in all multicellular organisms. An important family of nuclear receptors comprises those members that respond to steroid hormones, and which is subdivided in turn into estrogen receptor (ER) isoforms α and β (NR3A1 and A2, respectively), and a second subfamily of so-called oxosteroid receptors. The latter includes the androgen receptor (AR/NR3C4), the glucocorticoid receptor (GR/NR3C1), the mineralocorticoid receptor (MR/NR3C2) and the progesterone receptor (PR/NR3C3). Here we review recent advances in our understanding of the structure-and-function relationship of steroid nuclear receptors and discuss their implications for the etiology of human diseases. We focus in particular on the role played by AR dysregulation in both prostate cancer (PCa) and androgen insensitivity syndromes (AIS), but also discuss conditions linked to mutations of the GR gene as well as those in a non-steroidal receptor, the thyroid hormone receptor (TR). Finally, we explore how these recent results might be exploited for the development of novel and selective therapeutic strategies., E E P expresses her deepest gratitude to the generous and continuous private donations from Gemma E Carretero. E E P, P F P and P P acknowledge the RED Nacional de Receptores Nucleares (NurCaMeIn: SAF2017-71878-REDT and SAF2015-71878-REDT). E E P acknowledges the BFU-Retos2017-86906-R, P F P the SAF2014-57994-R, P P the SAF2017-88046-R and A R the RTI2018-096735-B-100 grants from the MINECO. E E P and P F P are thankful for the CaixaImpulse2017 (ARDIs) from La Caixa (Fundación Bancaria Caja de Ahorros y Pensiones de Barcelona, Obra Social La Caixa y Caixa Risc) and SGR2017 and LLAVOR2018 grants from the Generalitat de Catalunya. E E P acknowledges the F2I-FVAL and F2I-MiR grants from the EU FEDER and the Fundació Bosch i Gimpera (FBG)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development

  • Font-Díaz, Joan
  • Jiménez-Panizo, Alba
  • Caelles, Carme
  • Vivanco, María d. M.
  • Pérez, Paloma
  • Aranda, Ana
  • Estébanez-Perpiñá, Eva
  • Castrillo, Antonio
  • Ricote, M. Mercedes
  • Valledor, Annabel F.
Versión de autor del artículo, 93 páginas, 3 figuras 1 tabla, Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that act as biological sensors and use a combination of mechanisms to modulate positively and negatively gene expression in a spatial and temporal manner. The highly orchestrated biological actions of several NRs influence the proliferation, differentiation, and apoptosis of many different cell types. Synthetic ligands for several NRs have been the focus of extensive drug discovery efforts for cancer intervention. This review summarizes the roles in tumour growth and metastasis of several relevant NR family members, namely androgen receptor (AR), estrogen receptor (ER), glucocorticoid receptor (GR), thyroid hormone receptor (TR), retinoic acid receptors (RARs), retinoid X receptors (RXRs), peroxisome proliferator-activated receptors (PPARs), and liver X receptors (LXRs). These studies are key to develop improved therapeutic agents based on novel modes of action with reduced side effects and overcoming resistance., This work was supported by grants from the Spanish Ministry of Economy and Competitivity (MINECO) to AFV and CC (SAF2017-89510- R), to AA (SAF2017-83289-R), to MV (SAF2017-84934-R), to PP (SAF2017-88046-R), to EE (BFU2017-86906-R), and to the NuRCaMeIn network (SAF2017-90604REDT); grants from the Spanish Ministry of Science, Innovation and Universities (MCNU) and Fondo Europeo de Desarrollo Regional (FEDER) to MR (RTI2018-095928-B100) and AC (PID2019-104284RB-I00/AEI/10.13039/501100011033); a grant from Instituto de Salud Carlos III to AA (CIBERONC CB/16/00228); grants from the Autonomous Community of Madrid to AA (B2017/BMD-3724) and MR (MOIR-B2017/BMD-3684); grants from Fundació La Marato ´ de TV3 to CC (201605-30), AFV (201605-31) and MR (201605-32); a grant from the Government of the Autonomous Community of Basque Country, Department of Industry, Tourism and Trade to MV (Elkartek, KK-2018/ 00054); and a grant from La Caixa to EEP (CaixaImpulse-CI-0018). JFD received a fellowship from the Spanish Ministry of Science, Innovation and Universities (FPI, PRE2018-085579). The CNIC is supported by the MCNU and the Pro CNIC Foundation and is a Severo Ochoa Centre of Excellence (SEV-2015-0505). CIC bioGUNE is a Severo Ochoa Centre of Excellence (SEV-2016-0644), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Glucocorticoid Resistance: Interference between the Glucocorticoid Receptor and the MAPK Signalling Pathways

  • Sevilla, Lisa M.
  • Jiménez-Panizo, Alba
  • Alegre-Martí. Andrea
  • Estébanez-Perpiñá, Eva
  • Caelles, Carme
  • Pérez, Paloma
22 páginas, 4 figuras, Endogenous glucocorticoids (GCs) are steroid hormones that signal in virtually all cell types to modulate tissue homeostasis throughout life. Also, synthetic GC derivatives (pharmacological GCs) constitute the first-line treatment in many chronic inflammatory conditions with unquestionable therapeutic benefits despite the associated adverse effects. GC actions are principally mediated through the GC receptor (GR), a ligand-dependent transcription factor. Despite the ubiquitous expression of GR, imbalances in GC signalling affect tissues differently, and with variable degrees of severity through mechanisms that are not completely deciphered. Congenital or acquired GC hypersensitivity or resistance syndromes can impact responsiveness to endogenous or pharmacological GCs, causing disease or inadequate therapeutic outcomes, respectively. Acquired GC resistance is defined as loss of efficacy or desensitization over time, and arises as a consequence of chronic inflammation, affecting around 30% of GC-treated patients. It represents an important limitation in the management of chronic inflammatory diseases and cancer, and can be due to impairment of multiple mechanisms along the GC signalling pathway. Among them, activation of the mitogen-activated protein kinases (MAPKs) and/or alterations in expression of their regulators, the dual-specific phosphatases (DUSPs), have been identified as common mechanisms of GC resistance. While many of the anti-inflammatory actions of GCs rely on GR-mediated inhibition of MAPKs and/or induction of DUSPs, the GC anti-inflammatory capacity is decreased or lost in conditions of excessive MAPK activation, contributing to disease susceptibility in tissue- and disease- specific manners. Here, we discuss potential strategies to modulate GC responsiveness, with the dual goal of overcoming GC resistance and minimizing the onset and severity of unwanted adverse effects while maintaining therapeutic potential., This research was funded by grants to P.P. SAF2017-88046-R, PID2020-114652RB-I00, to E.E.-P. BFU-2017-86906-R, and to C.C. PID2020-119875RB-100 (from MICINN, Spanish Government); also, to E.E.-P. from G.E. Carretero Fund for Science, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The multivalency of the glucocorticoid receptor ligand-binding domain explains its manifold physiological activities

  • Jiménez-Panizo, Alba
  • Alegre-Martí, Andrea
  • Tettey, Theophilus T.
  • Fettweis, Gregory
  • Abella, Montserrat
  • Antón, Rosa
  • Johnson, Thomas A.
  • Kim, Sohyoung
  • Schiltz, R. Louis
  • Núñez-Barrios, Israel
  • Font-Diaz, Joan
  • Caelles, Carme
  • Valledor, Annabel F.
  • Pérez, Paloma
  • Rojas Mendoza, Ana M.
  • Fernández-Recio, Juan
  • Presman, Diego M.
  • Hager, Gordon L.
  • Fuentes-Prior, Pablo
  • Estébanez-Perpiñá, Eva
20 páginas, 7 figuras, The glucocorticoid receptor (GR) is a ubiquitously expressed transcription factor that controls metabolic and homeostatic processes essential for life. Although numerous crystal structures of the GR ligand-binding domain (GR-LBD) have been reported, the functional oligomeric state of the full-length receptor, which is essential for its transcriptional activity, remains disputed. Here we present five new crystal structures of agonist-bound GR-LBD, along with a thorough analysis of previous structural work. We identify four distinct homodimerization interfaces on the GR-LBD surface, which can associate into 20 topologically different homodimers. Biologically relevant homodimers were identified by studying a battery of GR point mutants including crosslinking assays in solution, quantitative fluorescence microscopy in living cells, and transcriptomic analyses. Our results highlight the relevance of non-canonical dimerization modes for GR, especially of contacts made by loop L1-3 residues such as Tyr545. Our work illustrates the unique flexibility of GR's LBD and suggests different dimeric conformations within cells. In addition, we unveil pathophysiologically relevant quaternary assemblies of the receptor with important implications for glucocorticoid action and drug design, E.E.-P. thanks the generosity of the Gemma E. Carretero Fund; MINECO [BFU2017-86906-R, SAF2017-71878-REDT, SAF2015-71878-REDT to E.E.-P., RTI2018-101500-B-I00 to P.F.-P., RTI2018-096735-B-100 to A.R.M., PID2019-110167RB-I00 to J.F.-R., SAF2017-89510-R to A.V.F. and C.C.]; G.L.H thanks the NIH Intramural Research Program; D.M.P was supported by CONICET. Funding for open access charge: Spanish Ministry of Science (MINECO)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The multimerization pathway of the glucocorticoid receptor

  • Alegre-Martí, Andrea
  • Jimenez-Panizo, Alba
  • Lafuente, Agustina L.
  • Johnson, Thomas A.
  • Montoya-Novoa, Inés
  • Peralta-Moreno, M. Nuria
  • Montanya-Valluguera, Pilar
  • Ponseti-Pons, Josep
  • Abella, Montserrat
  • Kim, Sohyoung
  • Diaz, Mireia
  • Vilaseca, Marta
  • Pérez, Paloma
  • Fernández-Recio, Juan
  • Rubio-Martínez, Jaime
  • Presman, Diego M.
  • Hager, Gordon L.
  • Fuentes-Prior, Pablo
  • Estébanez-Perpiñá, Eva
24 páginas, 7 figuras, The glucocorticoid receptor (GR) is a leading drug target due to its antiinflammatory and immunosuppressive roles. The functional oligomeric conformation of full-length GR (FL-GR), which is key for its biological activity, remains disputed. Here we present a new crystal structure of agonist-bound GR ligand-binding domain (GR-LBD) comprising eight copies of a noncanonical dimer. We verified the biological relevance of this dimer for receptor multimerization in wild-type and selected FL-GR mutants using molecular dynamics and crosslinking-mass spectrometry together with fluorescence microscopy and transcriptomic analysis in living cells. Self-association of this GR-LBD basic dimer in two mutually exclusive assemblies reveals clues for FL-GR multimerization and activity in cells. We propose a model for the structure of multidomain GR based on our new data and suggest a detailed oligomerization pathway. This model reconciles all currently available structural and functional information and provides a more comprehensive understanding of the rare disorder, generalized glucocorticoid resistance., This work was supported by the Intramural Research Program of the National Institutes of Health (NIH) (ZIA BC 005450), National Cancer Institute (Center for Cancer Research), Ministerio de Ciencia, Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI) (BFU2017-86906-R, PDC2021-121688- 100, PID2022-141399-OB-100, CPP2022-009586 to E.E.-P., JDC2022-048702-I to A.J.-P., JDC2023-051138-I to A.A.- M., PID2022-143215OB-I00 to J.F.-R., PID2023-1479660B- I00 to P .P .), Unidad de Excelencia María de Maeztu (CEX2021-001202-M to J.R.-M.), Agència de Gestió d’Ajuts Universitaris i de Recerca (A GA UR) - Generalitat de Catalunya (2021SGR01433 to E.E.-P. and 2021SGR00350 to J.R.-M.), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (ANPCyT) (PICT 2019–0397 to D.M.P .). E.E.-P . also acknowledges the support from the G.E. Carretero Fund. M.N.P.-M acknowledges the Universitat de Barcelona (UB) PREDOCSUB 2020 grant. The Intramural Research Program of the NIH and UB-CRAI funded the open access publication charges for this article., Peer reviewed